FDA approves Roche immunotherapy cocktail in liver cancer

The immunotherapy Tecentriq in combination with drug Avastin will give speedy access to cancer patients
Swiss drugmaker Roche said that the US Food and Drug Administration (FDA) approved its immunotherapy Tecentriq in combination with its drug Avastin for the most common kind of liver cancer.
The Tecentriq-Avastin mix for unresectable or metastatic hepatocellular carcinoma was approved under the FDA’s Real-Time Oncology Review pilot and Project Orbis initiative aimed at speedier access for patients, Roche said. 
The American Cancer Society estimated that more than 42,000 Americans will be diagnosed with liver cancer this year.


Comments

Post a Comment

Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product ramucirumab (Cyramza). The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. The CHMP adopted a new indication as follows: “Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib”. For information, the full indications for Cyramza will be as follows : Gastric cancer Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatm
Read more

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

The goal of Fred Hutch Global Oncology, says Dr. Hootie Warren, its newly named head, is "to figure out how we can adapt the incredibly exciting work that’s done here so that it can benefit people all around the world.” Photo by Robert Hood / Fred Hutch News Service Immunotherapy researcher and oncologist  Dr. Edus H. Warren  works on the front lines of a revolution. In his 24 years at Fred Hutchinson Cancer Research Center, Warren, who goes by the nickname “Hootie,” has contributed to jaw-dropping discoveries in harnessing the immune system to fight cancer. Today  immunotherapy  is considered the most exciting advance in decades, joining surgery, radiation therapy and chemotherapy as a fourth pillar of cancer care. Now, as the new head of  Fred Hutch Global Oncology , he is set to lead a revolution that could be just as transformative: improving cancer care in sub-Saharan Africa and other regions that do not always have access to even the first three pillars. Fred
Read more

Is Indian pharma ready to tap the European market?

According to the European Health Report 2015 issued by the World Health Organization (WHO), alcohol consumption, tobacco use and obesity are among the major public health problems in the European Region. But cardiovascular diseases and cancer are the leading causes of premature mortality. In 1998, cancer accounted for just over one third (37 per cent) of premature mortality, and this rose consistently to 43 per cent in 2012. According to WHO report, with more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe. On a global scale, cancer accounted for 8.2 million deaths (around 13 per cent of the total) in 2012.Tobacco consumption and excessive alcohol consumption cause about 40 per cent of the total cancer burden. The precise figures vary from country to country. The report further notes that if the consequences of inappropriate diet, obesity and insufficient physical activity are added, t
Read more